Roche Group's Genentech Announces FDA Approves Ocrevus Zunovo As The First And Only Twice-A-Year 10-Minute Subcutaneous Injection For People With Relapsing And Progressive Multiple Sclerosis
Roche Group's Genentech Announces FDA Approves Ocrevus Zunovo As The First And Only Twice-A-Year 10-Minute Subcutaneous Injection For People With Relapsing And Progressive Multiple Sclerosis
– Ocrevus Zunovo has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office –
– Ocrevus Zunovo有潜力扩大治疗选项，以满足没有静脉制造行业设施或存在静脉限制的中心，例如医生办公室 –
– This approval is backed by a decade of proven safety and efficacy data of Ocrevus IV, with over 350,000 people treated globally –
– 这一批准是基于超过350,000人全球接受治疗的Ocrevus静脉的十年安全性和疗效数据支持的 –
– Ocrevus Zunovo offers people with multiple sclerosis (MS) more options to access treatment based on their individual needs –
– Ocrevus Zunovo为多发性硬化（MS）患者提供更多根据个体需求进行治疗的选择 –
Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC) injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options.
罗氏集团成员亨利制药公司今日宣布，美国食品和药物管理局（FDA）已批准Ocrevus Zunovo（奥克雷利珠单抗和透明质酸酶-ocsq）用于治疗复发性多发性硬化症（RMS）和原发性进行性多发性硬化症（PPMS）。Ocrevus Zunovo是首款也是唯一一款每年两次由专业医疗人员（HCP）进行约10分钟皮下（SC）注射的批准药物，可用于这两种形式的多发性硬化症治疗，为患有多发性硬化症的人提供更多治疗期权。